Updates

Hutchison China Meditech - Out-licensing deal for lead product imminent

September 2010

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Excellent interims from Chi-Med, which came in ahead of expectations due mainly to the Chinese consumer healthcare business. Overall sales rose 29% to US$73.2m and pretax profit was US$2.1m against a forecast of breakeven. Chi-Med appears to be firing on all cylinders. The core China healthcare division grew by 25% to US$66.5m and operating profit by 28% to US$12.2m thanks to strong sales of its OTC medicines, particularly angina tablets. In addition sales of prescription products also grew strongly thanks to the inclusion of the drugs on the Essential Medicine List. The healthcare divisionâ€™s profitability fully offset both the operating loss in the drug R&D division, where sales rose 38% to US$2.6m and operating ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

First Derivatives

Kewill

Hutchison China Meditech -NÃ©stle deal for HMPL-004 drug (January 2013)

Hutchison China Meditech (September 2012)

Hutchison China Meditech - 2012 starts with a bang (April 2012)

Hutchison China Meditech (March 2012)

Hutchison China Meditech - Nets US$20m upfront collaboration payment from Astra Zeneca (January 2012)

Hutchison China Meditech - Broker says 600p sum of parts (September 2011)

Hutchison China Meditech - To distribute third party drugs (August 2011)

Hutchison China Meditech (April 2011)

Hutchison China Meditech - Pre-IPO funding ahead of NASDAQ float? (January 2011)

Hutchison China Meditech (October 2010)

Hutchison China Meditech - Great secrecy shrouds R&D division (July 2010)

Hutchison China Meditech - 17 of 307 Chinese "essential medicines" (June 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X